Literature DB >> 3009522

Characteristics of human erythrocyte insulin-like growth factor I receptors.

T Izumi, M Kasuga, T Kadowaki, N Hizuka, F Takaku, Y Akanuma.   

Abstract

The scarcity of purified materials has prevented studies of the mechanism of insulin-like growth factor I (IGF-I) action. Recently, an IGF-I analog, Thr59-IGF-I, was synthesized by recombinant DNA technology. We found that this analog had binding characteristics similar to those of natural IGF-I in the radioreceptor assay system. We used this analog to characterize human erythrocyte IGF-I receptors as follows. Erythrocytes from 33 normal subjects specifically bound 6.9 +/- 0.7% (mean +/- SD)/2.8 X 10(9) cells/ml. Scatchard analysis of the binding data showed that the total number of receptors per erythrocyte was 13, and the affinity constant was 1.26 X 10(9) M-1, similar to that of other human IGF-I receptors previously reported. We also examined IGF-I receptors in patients with insulin receptor abnormalities. Although the specific values of IGF-I binding to erythrocytes were decreased or increased in parallel with those of insulin, the degrees of decrease or increase were much smaller. This suggests that the expression of insulin receptors and that of IGF-I receptors are discordant.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009522     DOI: 10.1210/jcem-62-6-1206

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  2 in total

1.  Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro.

Authors:  V F Tapson; M Boni-Schnetzler; P F Pilch; D M Center; J S Berman
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

2.  Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver.

Authors:  J F Caro; J Poulos; O Ittoop; W J Pories; E G Flickinger; M K Sinha
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.